Nanogen Struggles Through Another Quarter, Targets 2005 Revenue Growth | GenomeWeb

Nanogen last week reported a decline in its fiscal 2004 second-quarter revenues and an increase in its net loss, as the firm struggled with lagging sales of its molecular diagnostics products to clinical laboratories.

The San Diego-based firm posted revenues of $1.1 million for the quarter, compared to $1.7 million for the comparable quarter in 2003. Its product revenues were $477,000 for the quarter, down from product revenues of $662,000 in the second quarter of 2003.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.